Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.36 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064331 | 0.91 | CACNA1H (0.45) | RIPK1CACNA1HAOC3LTB4R2BCL2A1 | |
| Trifluoroacetic Acid SCHEMBL3054195 | 0.86 | CACNA1H (0.42) | RIPK1CACNA1HAOC3LTB4R2BCL2A1 | |
| SCHEMBL4736030 | 0.85 | CACNA1H (0.47) | CACNA1HAOC3LTB4R2BCL2A1CNR2 | |
| SCHEMBL3071006 | 0.85 | CACNA1H (0.47) | CACNA1HAOC3LTB4R2BCL2A1CNR2 | |
| SCHEMBL3065942 | 0.83 | CACNA1H (0.46) | RIPK1CACNA1HAOC3LTB4R2BCL2A1 | |
| SCHEMBL3054673 | 0.82 | NR1H2 (0.41) | RIPK1CACNA1HAOC3LTB4R2BCL2A1 | |
| SCHEMBL3815393 | 0.82 | CACNA1H (0.45) | CACNA1HAOC3LTB4R2BCL2A1CNR2 | |
| SCHEMBL3819450 | 0.82 | CACNA1H (0.46) | RIPK1CACNA1HAOC3LTB4R2BCL2A1 | |
| SCHEMBL3816063 | 0.81 | CACNA1H (0.45) | CACNA1HAOC3LTB4R2BCL2A1CNR2 | |
| SCHEMBL3061182 | 0.80 | CACNA1H (0.40) | RIPK1CACNA1HAOC3LTB4R2GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | claimed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | RIPK1 2974/4885CACNA1H 13/4885AOC3 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.